Drug Patent Watch
APRIL 5, 2022
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…. The post The value of method of use patent claims in protecting your therapeutic assets appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
APRIL 5, 2022
It’s no secret that digital technologies are playing a significant role when it comes to shaping the next era of healthcare. Necessity accelerated the adoption of new and sophisticated technologies and systems throughout the COVID-19 pandemic, but this seismic shift towards digital health has opened up a gap in education. To successfully navigate the potential of digital technologies in healthcare, attention must be focused on upskilling professionals in the field to equip them with the necessar
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
APRIL 8, 2022
Alexion Pharma UK, AstraZeneca’s Rare Disease group, announces the recommendation of its pivotal neurofibromatosis treatment
Drug Channels
APRIL 5, 2022
The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. For 2021, we estimate that the three biggest PBMs accounted for 80% of total equivalent prescription claims. Significant business relationships among the largest companies continue to shift market share.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Patent Watch
APRIL 7, 2022
Annual Drug Patent Expirations for BAXDELA Baxdela is a drug marketed by Melinta and is included in two NDAs. It is available from one supplier. There are thirteen patents protecting…. The post New patent for Melinta drug BAXDELA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
APRIL 4, 2022
The National Institutes of Health (NIH) is funding a nationwide study in the US to support research on long-COVID, chronic COVID, or as it’s scientifically known, post-acute sequelae of SARS-CoV-2 (PASC) in children. An estimated 10% to 30% of adults who contract COVID-19 suffer from long COVID. Though speciality departments and independent institutions have opened to study chronic COVID in adults, little research has been done to evaluate the long-term effects of the virus on children.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Channels
APRIL 4, 2022
Rare Disease Innovation & Partnering Summit. Hybrid Event May 17-19, 2022 | Boston, MA www.informaconnect.com/rare. Don’t miss the Rare Disease Innovation & Partnering Summit, coming up May 17-19, 2022 in Boston, MA. Visit www.informaconnect.com/rare for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to April 29, 2022.*.
Outsourcing Pharma
APRIL 7, 2022
The US Department of Health and Human Serviceâs Office of Research Integrity has uncovered evidence that Toni Brand committed fraud in a number of reports.
pharmaphorum
APRIL 6, 2022
Ensuring that patients remain consistent with their therapies is one of the major challenges facing healthcare, so what if you could make treatment a game? That’s the potential behind game-based digital therapeutics and it’s drawing a lot of interest, finds Ben Hargreaves. The impact of video games on modern culture can be felt by even those that have little or no interest in them.
Pharma Times
APRIL 4, 2022
Golden Ticket programme is open to early-stage life sciences companies and biotech start-ups which are focusing on cutting edge therapies
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
APRIL 8, 2022
Today’s guest post comes from Michael Carr, CoAssist Group Vice President at AssistRx. Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. He goes on to describe four new categories of patient solutions and pharmacy models specific to this growing market segment. To learn more about CoAssist and AssistRx specialty therapy initiation and patient support services, click here to schedule a meeting with AssistRx at the Asembia Specialty Pharmacy Summit on
Outsourcing Pharma
APRIL 7, 2022
Experts from the Decentralized Trials and Research Alliance and Rafael Pharmaceuticals discuss progress and possibilities during Clinical Development Advances.
pharmaphorum
APRIL 6, 2022
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests healthy sales revenue from Eli Lilly-partnered SGLT2 inhibitor Jardiance. The German group has just reported a 28% increase in Jardiance (empagliflozin) sales to €3.9 billion in 2021, buoyed by new approval in heart failure, which was accompanied by a 25% gain for pulmonary fibrosis therapy Ofev (nintedanib) to €2.5 billion.
Pharma Times
APRIL 4, 2022
Investments will enhance the development of lipid systems manufacturing, while also boosting the development of gene therapies
NY Times
APRIL 6, 2022
India makes many of the world’s drugs, but treatments for rare diseases like spinal muscular atrophy are imported and prohibitively costly. In desperation, parents are raising funds on social media.
Outsourcing Pharma
APRIL 6, 2022
The excipients, equipment, and API companies have joined forces on Inhalation Together, an initiative aimed at advancing dry-powder inhalation solutions.
pharmaphorum
APRIL 8, 2022
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year.
Pharma Times
APRIL 5, 2022
Data has shown that treatment with Kesimpta is associated with fewer relapses and reduced risk of worsening disability
NY Times
APRIL 6, 2022
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
Outsourcing Pharma
APRIL 5, 2022
Leaders from some of the industryâs most notable companies are working together to streamline and automate IDMP workflow and come up with various standards.
pharmaphorum
APRIL 6, 2022
2021 was a big year in investment financing for US digital health companies, but there are signs that it may be a high watermark. In the first three months of this year there were 183 deals worth a total of $6 billion, giving an average size per deal of just under $33 million, according to venture fund Rock Health’s latest update on the sector.
Pharma Times
APRIL 6, 2022
New Dublin development office will be responsible for paediatric clinical trials for seven products across 18 countries
NY Times
APRIL 7, 2022
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
Pharma Mirror
APRIL 8, 2022
Cambridge, UK, CellCentric, aclinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments of Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Both have stellar experience and track records in oncology research and development.
pharmaphorum
APRIL 4, 2022
Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway. The US regulator has cleared Kite’s CD19-targeted CAR-T Yescarta (axicabtagene ciloleucel) for people with large B-cell lymphoma (LBCL) refractory to one earlier therapy, or who have relapsed within 12 moths of first-line chemo-immunotherapy.
Pharma Times
APRIL 7, 2022
NICE recommends avelumab as treatment for adults with locally advanced or metastatic urothelial cancer
Drug Patent Watch
APRIL 8, 2022
Annual Drug Patent Expirations for ZOLADEX Zoladex is a drug marketed by Tersera and is included in two NDAs. It is available from two suppliers. There are two patents protecting…. The post New patent expiration for Tersera drug ZOLADEX appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Mirror
APRIL 8, 2022
BARCELONA, Spain and Dundee, UK, a global biopharmaceutical company focused on skin health, today announced a research collaboration with the University of Dundee, a top-ranked university in the UK in biological sciences, to develop a novel approach against chronic and debilitating dermatology diseases where itch, or pruritus, plays a dominant role.
pharmaphorum
APRIL 6, 2022
Parliamentarians in the UK have warned that the government is not making the effort needed to reach its target of diagnosing three quarters of cancer cases at an early stage. If urgent action is not taken, England is at risk of remaining a laggard in cancer care among comparable countries like Australia and Canada, according to a new report from the Health and Social Care Committee.
Pharma Times
APRIL 5, 2022
In contrast to conventional methods, Evonetix uses thermal control which offers greater accuracy and selectivity
Board Vitals - Pharmacist
APRIL 8, 2022
Funding is something that must be considered when determining your undergraduate and graduate academic goals for nursing school. Nursing school is expensive. Depending on the type of school and nursing program you enroll in, total tuition can range from $6,000 for an associate degree to $100,000 for an advanced degree. Luckily, many organizations offer funding options to nursing students from grants to student loans to scholarships.
Pharma Mirror
APRIL 7, 2022
Let’s face it, dealing with a terminal illness diagnosis will never be an easy task and there’s not much you can do to mitigate the pain. However, there are a few steps that you can take to make the whole ordeal a bit more manageable for the person diagnosed and those around them. There are a few emotional chapters you’ll need to close as well as some practical matters that you should get out of the way if you are diagnosed with a terminal illness.
pharmaphorum
APRIL 4, 2022
Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem of antibiotic resistance. The Fund – set up as a public-private partnership by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – started life with $1 billion earmarked to support companies trying to develop antibiotics that can be used to replace those that have star
Pharma Times
APRIL 7, 2022
Spin-off company will focus on developing therapies in areas of inflammation and immunometabolism
Board Vitals - Pharmacist
APRIL 7, 2022
If you’re like most nursing students, your clinical experiences will be either the best or worse (or potentially both) part of nursing school. There are many factors that influence the quality of your clinical experience. Most of which are out of your control, but despite that, you hold the keys to success during your nursing school clinicals. . Be a Learner First.
Expert insights. Personalized for you.
124 
Let's personalize your content